January 2026
Psychedelic-assisted therapy
What January 2026's 21 new studies found, synthesized from the papers below. All Psychedelic-assisted therapy research →
The synthesis
Synthesized from 21 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psychedelic-assisted therapy, psychedelic therapy, assisted psychotherapy, drug-assisted therapy, then ranked by relevance.
Research in January 2026 indicates that psychedelic-assisted therapy shows promise for conditions like depression, PTSD, and substance use disorders, with psilocybin demonstrating rapid and sustained antidepressant effects and MDMA showing efficacy for PTSD, though challenges remain in cost, accessibility, and standardization. However, the evidence is mixed, with some studies highlighting risks such as new-onset OCD after MDMA therapy and the need for more rigorous, diverse, and long-term research to confirm efficacy and safety.
Confidence in the evidence
Low-Moderate- The evidence includes multiple systematic reviews and meta-analyses (e.g., article_id 19483, 19451) but also relies on case series (article_id 28834) and surveys (article_id 27772, 18105), limiting generalizability.
- Study designs vary from RCTs to open-label trials and qualitative reviews, with some studies noting methodological concerns and lack of blinding (article_id 19483, 30125).
- Findings are generally positive but inconsistent across conditions, with one case report (article_id 29427) showing adverse effects, and several studies emphasize the need for larger, more diverse samples (article_id 19494, 30125).
- Many studies are narrative reviews or theoretical pieces (e.g., article_id 18927, 27883, 31159) that do not provide original empirical data, reducing overall confidence.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration. 2026 | commentary | Unclear | This commentary argues for ethical and reciprocal collaboration with Indigenous communities in psychedelic science, emphasizing sovereignty and benefit-sharing. | |
| PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION 2026 | narrative review | Supports | Psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects with high response and remission rates, though challenges in cost and accessibility exist. | |
| These aren’t the beliefs you’re looking for: on the limits of affect-neutral accounts of psychedelic therapy 2026 | theoretical | Unclear | This paper argues that belief disruption alone is insufficient to explain therapeutic outcomes in psychedelic therapy, emphasizing the need for a positive shift in affective valence. | |
| Ethics of Psychedelic-Assisted Psychotherapy 2026 | theoretical | Unclear | This article explores ethical considerations in psychedelic-assisted psychotherapy through narrative and virtue ethics, advocating for holistic and patient-centered care. | |
| Ketamine assisted psychotherapy in postpartum mood and anxiety disorders: a limited case series 2026 | case series | 3 | Supports | Ketamine-assisted psychotherapy showed utility in treating postpartum mood and anxiety disorders in a limited case series of three patients. |
| The Therapeutic Potential of Psychedelics for Treatment-resistant Depression: Reality or Hallucination? A Systematic Review. 2026 | systematic review | 15 | Supports | This systematic review of 15 studies (10 RCTs, 5 open-label) found that psychedelics represent an alternative therapeutic approach for treatment-resistant depression, suggesting efficacy across different substances. |
| The case for an integrative model: Hypotheses and rationale for integrative MDMA-Assisted Psychotherapy (IMAP) 2026 | theoretical | Unclear | This paper proposes an Integrative MDMA-Assisted Psychotherapy model rooted in trauma-focused traditions, diverging from the original MAPS manual to improve standardization. | |
| Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis. 2026 | systematic review and meta-analysis | 12 | Mixed | This meta-analysis of 12 studies found that the quantity of psychological therapy sessions was not consistently associated with depressive symptom reduction in psychedelic-assisted therapy. |
| Set and Setting for Psychedelic Harm Reduction 2026 | theoretical | Unclear | This paper provides a framework for set and setting in psychedelic harm reduction, discussing how context influences outcomes across therapeutic, clinical, ritualistic, and recreational modalities. | |
| Guiding Through Challenging Psychedelic Experiences and “Bad Trips” 2026 | case series | 3 | Unclear | This article presents three case reports and proposes a stepwise approach for managing challenging psychedelic experiences, including supportive care and rescue medication. |
| Psychedelics in the age of reproducibility: Reflections on aura, set and setting and the medicalization of mystical-type experiences. 2026 | theoretical | Unclear | This article uses Walter Benjamin's concept of 'aura' to examine tensions between authenticity and standardization when psychedelic experiences are medicalized in clinical settings. | |
| Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder. 2026 | review | Supports | Psilocybin demonstrates rapid and sustained symptom relief for MDD by enhancing neuroplasticity and brain connectivity, but regulatory barriers and stigma hinder broader application. | |
| Protecting Patient Autonomy in Psychedelic-Assisted Psychotherapy: A Nursing Ethics Perspective 2026 | theoretical | Unclear | This article examines patient autonomy in psychedelic-assisted psychotherapy from a nursing ethics perspective. | |
| Spiritual wellbeing in psychedelic-assisted therapy with palliative care populations: An analysis of outcome measures 2026 | literature review | 286 | Unclear | This review identified three spiritual wellbeing measures suitable for use in psychedelic-assisted therapy research with palliative care populations, noting inconsistent reporting of such outcomes. |
| Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature. 2026 | narrative review | Supports | This narrative review found that population surveys, observational studies, and clinical trials suggest psychedelics are associated with symptom reduction in substance use disorders, though methodological concerns limit generalizability. | |
| Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians. 2026 | survey | 41 | Unclear | A survey of 41 Swiss physicians found that PAT is used primarily for depression, anxiety, PTSD, and chronic pain, with psilocybin preferred for depression and MDMA for PTSD. |
| Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs. 2026 | narrative review | Supports | This review includes psychedelic-assisted pharmacotherapy as a next-generation approach for depressive disorders, particularly for treatment-resistant depression. | |
| Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation 2026 | cross-sectional survey | 534 | Supports | A survey of 534 daily nicotine users found that familiarity with psilocybin-assisted psychotherapy predicted greater perceived credibility and interest compared to standard cessation interventions. |
| Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy" 2026 | narrative review | Mixed | This review found that while psychotherapy is considered core to psychedelic-assisted therapy, studies differ in therapeutic orientation and therapist involvement, and outcomes may not depend on therapy hours. | |
| New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report 2026 | case report | 1 | Opposes | A case report describes new-onset obsessive-compulsive disorder in a 31-year-old woman following MDMA-assisted psychotherapy, suggesting a potential risk for adverse psychiatric outcomes. |
| Attitudes toward psychedelic therapy among medical and nursing students: A cross-sectional survey study. 2026 | cross-sectional survey | 325 | Unclear | A survey of 325 medical and nursing students found that medical students had higher perceived knowledge and more favorable attitudes toward psychedelic therapy, while nursing students associated psychedelics with psychiatric risk. |
This commentary argues for ethical and reciprocal collaboration with Indigenous communities in psychedelic science, emphasizing sovereignty and benefit-sharing.
commentary
Psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects with high response and remission rates, though challenges in cost and accessibility exist.
narrative review
This paper argues that belief disruption alone is insufficient to explain therapeutic outcomes in psychedelic therapy, emphasizing the need for a positive shift in affective valence.
theoretical
This article explores ethical considerations in psychedelic-assisted psychotherapy through narrative and virtue ethics, advocating for holistic and patient-centered care.
theoretical
Ketamine-assisted psychotherapy showed utility in treating postpartum mood and anxiety disorders in a limited case series of three patients.
case series Sample size: 3
This systematic review of 15 studies (10 RCTs, 5 open-label) found that psychedelics represent an alternative therapeutic approach for treatment-resistant depression, suggesting efficacy across different substances.
systematic review Sample size: 15
This paper proposes an Integrative MDMA-Assisted Psychotherapy model rooted in trauma-focused traditions, diverging from the original MAPS manual to improve standardization.
theoretical
This meta-analysis of 12 studies found that the quantity of psychological therapy sessions was not consistently associated with depressive symptom reduction in psychedelic-assisted therapy.
systematic review and meta-analysis Sample size: 12
This paper provides a framework for set and setting in psychedelic harm reduction, discussing how context influences outcomes across therapeutic, clinical, ritualistic, and recreational modalities.
theoretical
This article presents three case reports and proposes a stepwise approach for managing challenging psychedelic experiences, including supportive care and rescue medication.
case series Sample size: 3
This article uses Walter Benjamin's concept of 'aura' to examine tensions between authenticity and standardization when psychedelic experiences are medicalized in clinical settings.
theoretical
Psilocybin demonstrates rapid and sustained symptom relief for MDD by enhancing neuroplasticity and brain connectivity, but regulatory barriers and stigma hinder broader application.
review
This article examines patient autonomy in psychedelic-assisted psychotherapy from a nursing ethics perspective.
theoretical
This review identified three spiritual wellbeing measures suitable for use in psychedelic-assisted therapy research with palliative care populations, noting inconsistent reporting of such outcomes.
literature review Sample size: 286
This narrative review found that population surveys, observational studies, and clinical trials suggest psychedelics are associated with symptom reduction in substance use disorders, though methodological concerns limit generalizability.
narrative review
A survey of 41 Swiss physicians found that PAT is used primarily for depression, anxiety, PTSD, and chronic pain, with psilocybin preferred for depression and MDMA for PTSD.
survey Sample size: 41
This review includes psychedelic-assisted pharmacotherapy as a next-generation approach for depressive disorders, particularly for treatment-resistant depression.
narrative review
A survey of 534 daily nicotine users found that familiarity with psilocybin-assisted psychotherapy predicted greater perceived credibility and interest compared to standard cessation interventions.
cross-sectional survey Sample size: 534
This review found that while psychotherapy is considered core to psychedelic-assisted therapy, studies differ in therapeutic orientation and therapist involvement, and outcomes may not depend on therapy hours.
narrative review
A case report describes new-onset obsessive-compulsive disorder in a 31-year-old woman following MDMA-assisted psychotherapy, suggesting a potential risk for adverse psychiatric outcomes.
case report Sample size: 1
A survey of 325 medical and nursing students found that medical students had higher perceived knowledge and more favorable attitudes toward psychedelic therapy, while nursing students associated psychedelics with psychiatric risk.
cross-sectional survey Sample size: 325
Points of agreement
- Multiple reviews and meta-analyses indicate that psilocybin and other psychedelics show rapid and sustained antidepressant effects, particularly for treatment-resistant depression (article_id 17642, 19483, 19494).
- Several studies emphasize the importance of set and setting, therapeutic context, and ethical considerations in psychedelic therapy (article_id 28089, 30525, 31159).
- There is agreement that psychedelic-assisted therapy faces challenges in standardization, accessibility, and cost (article_id 17642, 19494, 27298).
- Studies converge on the need for more rigorous, diverse, and long-term research to establish efficacy and safety (article_id 19483, 19494, 30125).
Conflicts
- One study found that the quantity of psychotherapy sessions was not associated with depressive symptom reduction (article_id 19451), while another review notes that psychotherapy is considered a core element but its role is poorly defined (article_id 27298).
- Most evidence supports efficacy, but a case report (article_id 29427) documents new-onset OCD after MDMA therapy, highlighting potential adverse effects not captured in positive trials.
- Attitudes toward psychedelic therapy differ between medical and nursing students, with nursing students more likely to associate psychedelics with psychiatric risk (article_id 30119).
Gaps
- Long-term outcomes and durability of effects are not well-studied (article_id 17642, 19494).
- Most studies lack diverse populations, limiting generalizability (article_id 19483, 30125).
- The role of psychotherapy in psychedelic-assisted therapy remains unclear, with inconsistent findings on whether therapy hours affect outcomes (article_id 19451, 27298).
- Safety concerns, such as the risk of triggering obsessive-compulsive symptoms, are underreported and require further investigation (article_id 29427).
- Spiritual wellbeing outcomes are inconsistently measured in psychedelic research (article_id 27297).